Entero Therapeutics to Acquire 03 Life Sciences
Ticker: GRDX · Form: 8-K · Filed: Jul 8, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pharmaceutical
TL;DR
Entero Therapeutics is buying 03 Life Sciences, deal expected to close Q3 2025.
AI Summary
Entero Therapeutics, Inc. announced on July 3, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of 03 Life Sciences. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions. This acquisition aims to expand Entero Therapeutics' pipeline and market presence.
Why It Matters
This acquisition could significantly expand Entero Therapeutics' product offerings and market reach in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, regulatory approval, and market reception.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant and acquirer
- 03 Life Sciences (company) — Target company to be acquired
- July 3, 2025 (date) — Date of the definitive agreement
- Third quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of the agreement announced by Entero Therapeutics?
Entero Therapeutics, Inc. announced that it has entered into a definitive agreement to acquire all outstanding equity interests of 03 Life Sciences.
When is the acquisition of 03 Life Sciences expected to close?
The transaction is expected to close in the third quarter of 2025.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions.
What was Entero Therapeutics, Inc. formerly known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc. (effective 20210921), AzurRx BioPharma, Inc. (effective 20141103), and BioPharma d'Azur, Inc. (effective 20140331).
What is the principal executive office address for Entero Therapeutics, Inc.?
The address of the principal executive offices is 777 Yamato Road, Suite 502, Boca Raton, Florida 33431.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 8, 2025 regarding Entero Therapeutics, Inc. (GRDX).